Adagene Stock Today
| ADAG Stock | USD 1.93 0.06 3.21% |
PerformanceOK
| Odds Of DistressQuite High
|
Adagene is trading at 1.93 as of the 24th of July 2025. This is a 3.21 percent increase since the beginning of the trading day. The stock's lowest day price was 1.87. Adagene has more than 68 % chance of experiencing financial distress in the next few years of operation. However, it had a very ok returns during the last 90 days. The performance scores are derived for the period starting the 25th of April 2025 and ending today, the 24th of July 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 9th of February 2021 | Category Healthcare | Classification Health Care |
Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company was incorporated in 2011 and is headquartered in Suzhou, China. Adagene Inc operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 47.11 M outstanding shares of which 77.17 K shares are presently shorted by private and institutional investors with about 1.16 trading days to cover. More on Adagene
Moving together with Adagene Stock
Moving against Adagene Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Adagene Stock Highlights
| Chairman, Founder | Peter Luo | ||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | ||||
| Average Analyst Recommendation | |||||
Debt LevelsAdagene can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Adagene's financial leverage. It provides some insight into what part of Adagene's total assets is financed by creditors.
| |||||
Adagene (ADAG) is traded on NASDAQ Exchange in USA. It is located in Building C14, Suzhou, China, 215123 and employs 138 people. Adagene is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 90.77 M. Adagene conducts business under Biotechnology sector and is part of Health Care industry. The entity has 47.11 M outstanding shares of which 77.17 K shares are presently shorted by private and institutional investors with about 1.16 trading days to cover.
Adagene currently holds about 168.04 M in cash with (29.7 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.87, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Adagene Probability Of Bankruptcy
Ownership AllocationAdagene holds a total of 47.11 Million outstanding shares. 30% of Adagene outstanding shares are owned by other corporate entities. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Adagene Ownership Details
Adagene Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Bnp Paribas Arbitrage, Sa | 2025-03-31 | 1.7 K | |
| Sbi Securities Co Ltd | 2025-03-31 | 76.0 | |
| Rhumbline Advisers | 2025-03-31 | 0.0 | |
| Kamunting Street Cap Management, L.p. | 2025-03-31 | 0.0 | |
| Exome Asset Management Llc | 2024-12-31 | 0.0 | |
| General Atlantic Llc | 2025-03-31 | 3.8 M | |
| Sc China Holding Ltd | 2025-03-31 | 1.3 M | |
| Fmr Inc | 2025-03-31 | 1.2 M | |
| Fidelity International Ltd | 2025-03-31 | 749.4 K | |
| Mill Creek Capital Advisors Llc | 2025-03-31 | 199.6 K | |
| Barclays Plc | 2025-03-31 | 122.5 K |
Adagene Historical Income Statement
Adagene Stock Against Markets
Adagene Corporate Management
| Alexander Goergen | VP Development | Profile | |
| Songmao Zheng | VP Pharmacology | Profile | |
| Jiping MD | Executive Development | Profile | |
| Man MBA | CFO Director | Profile | |
| Guizhong Liu | Head Pharmacology | Profile | |
| Xiaohong She | Senior Operations | Profile |
Already Invested in Adagene?
The danger of trading Adagene is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Adagene is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Adagene. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Adagene is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Adagene is a strong investment it is important to analyze Adagene's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Adagene's future performance. For an informed investment choice regarding Adagene Stock, refer to the following important reports: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Adagene. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For more detail on how to invest in Adagene Stock please use our How to Invest in Adagene guide.You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Adagene. If investors know Adagene will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Adagene listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.74) | Revenue Per Share | Quarterly Revenue Growth (0.87) | Return On Assets | Return On Equity |
The market value of Adagene is measured differently than its book value, which is the value of Adagene that is recorded on the company's balance sheet. Investors also form their own opinion of Adagene's value that differs from its market value or its book value, called intrinsic value, which is Adagene's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Adagene's market value can be influenced by many factors that don't directly affect Adagene's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Adagene's value and its price as these two are different measures arrived at by different means. Investors typically determine if Adagene is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Adagene's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.